Abstract

In the June 2019 issue of Journal of Child and Adolescent Psychopharmacology (vol. 29, no. 5, pp. 324–339), the article “New Formulations of Stimulants: An Update for Clinicians,” by Steingard et al. requires correction.
In the original publication, the article incorrectly described the Adhansia XRTM extended-release formulation by stating that the formulation “…utilizes two different types of multilayer beads (MPH microparticles). Twenty percent of the beads are coated with an IR layer and 80% are coated with a controlled release (ER) layer.”
This sentence should read: “…
In addition, the article referred to an 80 mg dosage strength. Adhansia XR is not available as an 80 mg dosage strength but is available as an
The article also stated: “According to the manufacturer, doses greater than 70 mg/day in pediatric patients and 85 mg/day in adults have been associated with a disproportionate increase in adverse reactions.”
This sentence has been amended to read: “
Lastly, when speaking to Adhansia XR, the article read: “The construction of this formulation results in an extended duration with a biphasic pattern of absorption and accumulation.”
This sentence now reads: “
The online version of the article has been corrected to reflect these changes. The authors wish to apologize for these errors.
